Literature DB >> 10665501

Creutzfeldt-Jakob disease profile in patients homozygous for the PRNP E200K mutation.

E S Simon1, E Kahana, J Chapman, T A Treves, R Gabizon, H Rosenmann, N Zilber, A D Korczyn.   

Abstract

We identified 70 Creutzfeldt-Jakob disease patients with the previously described E200K mutation in the prion protein gene. The purpose of this study was to define the clinical features of E200K homozygous patients (n = 5), compared with heterozygotes. We found a statistically significant younger age at disease onset for the homozygous patients, although the average age at onset in this group was still in midlife. Disease features were not statistically different in the two groups. Possible explanations are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10665501

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  13 in total

1.  Profoundly different prion diseases in knock-in mice carrying single PrP codon substitutions associated with human diseases.

Authors:  Walker S Jackson; Andrew W Borkowski; Nicki E Watson; Oliver D King; Henryk Faas; Alan Jasanoff; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

2.  Creutzfeldt-Jakob disease associated with a V203I homozygous mutation in the prion protein gene.

Authors:  Junji Komatsu; Kenji Sakai; Tsuyoshi Hamaguchi; Yu Sugiyama; Kazuo Iwasa; Masahito Yamada
Journal:  Prion       Date:  2014       Impact factor: 3.931

3.  Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins.

Authors:  Emmanuel A Asante; Ian Gowland; Andrew Grimshaw; Jacqueline M Linehan; Michelle Smidak; Richard Houghton; Olufunmilayo Osiguwa; Andrew Tomlinson; Susan Joiner; Sebastian Brandner; Jonathan D F Wadsworth; John Collinge
Journal:  J Gen Virol       Date:  2009-03       Impact factor: 3.891

4.  Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers.

Authors:  Hedok Lee; Hanna Rosenmann; Joab Chapman; Peter B Kingsley; Chen Hoffmann; Oren S Cohen; Esther Kahana; Amos D Korczyn; Isak Prohovnik
Journal:  Brain       Date:  2009-03-24       Impact factor: 13.501

5.  The Effects of Ca2+ Concentration and E200K Mutation on the Aggregation Propensity of PrPC: A Computational Study.

Authors:  Alessandro Marrone; Nazzareno Re; Loriano Storchi
Journal:  PLoS One       Date:  2016-12-13       Impact factor: 3.240

6.  Fatal prion disease in a mouse model of genetic E200K Creutzfeldt-Jakob disease.

Authors:  Yael Friedman-Levi; Zeev Meiner; Tamar Canello; Kati Frid; Gabor G Kovacs; Herbert Budka; Dana Avrahami; Ruth Gabizon
Journal:  PLoS Pathog       Date:  2011-11-03       Impact factor: 6.823

7.  Understanding and exploiting interactions between cellular proteostasis pathways and infectious prion proteins for therapeutic benefit.

Authors:  Unekwu M Yakubu; Celso S G Catumbela; Rodrigo Morales; Kevin A Morano
Journal:  Open Biol       Date:  2020-11-25       Impact factor: 6.411

8.  PrP(ST), a soluble, protease resistant and truncated PrP form features in the pathogenesis of a genetic prion disease.

Authors:  Yael Friedman-Levi; Michal Mizrahi; Kati Frid; Orli Binyamin; Ruth Gabizon
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

9.  Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia.

Authors:  Pietro Fratta; Mark Poulter; Tammaryn Lashley; Jonathan D Rohrer; James M Polke; Jon Beck; Natalie Ryan; Davina Hensman; Sarah Mizielinska; Adrian J Waite; Mang-Ching Lai; Tania F Gendron; Leonard Petrucelli; Elizabeth M C Fisher; Tamas Revesz; Jason D Warren; John Collinge; Adrian M Isaacs; Simon Mead
Journal:  Acta Neuropathol       Date:  2013-07-02       Impact factor: 17.088

10.  A case report of genetic prion disease with two different PRNP variants.

Authors:  Megan Piazza; Thomas W Prior; Prabhjot S Khalsa; Brian Appleby
Journal:  Mol Genet Genomic Med       Date:  2020-01-17       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.